

ICU mortality similar for patients with hematologic CA \pm chemo

May 26 2018



(HealthDay)—Short-term mortality is similar among patients with

hematologic cancer who receive chemotherapy while in the intensive care unit (ICU) versus those who do not, according to a study published online May 4 in *Cancer*.

Stephen M. Pastores, M.D., from the Memorial Sloan-Kettering Cancer Center in New York City, and colleagues retrospectively reviewed the outcomes of 181 patients with [hematologic malignancies](#) who received [chemotherapy](#) in the ICU at a single center versus a matched cohort of ICU patients who did not receive chemotherapy.

The researchers found that the ICU and hospital mortality rates were 25 and 42 percent, respectively, for [chemotherapy patients](#), compared to 22 and 33 percent, respectively, for non-chemotherapy patients. Patients who did receive chemotherapy had a significantly longer length of stay in the ICU (median, six versus three days; P

"Short-term mortality was similar among patients with hematologic malignancies who did and did not receive chemotherapy in the ICU, although patients who received chemotherapy had increased resource utilization," the authors write. "These results may inform ICU triage and goals-of-care discussions with patients and their families regarding outcomes after receiving chemotherapy in the ICU."

More information: [Abstract/Full Text \(subscription or payment may be required\)](#)

Copyright © 2018 [HealthDay](#). All rights reserved.

Citation: ICU mortality similar for patients with hematologic CA ± chemo (2018, May 26) retrieved 26 December 2022 from <https://medicalxpress.com/news/2018-05-icu-mortality-similar-patients-hematologic.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.